Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model

Background: Hypertrophic cardiomyopathy (HCM) patients often present with diastolic dysfunction and a normal to supranormal systolic function. To counteract this hypercontractility, guideline therapies advocate treatment with beta-adrenoceptor and Ca(2+) channel blockers. One well established pathom...

Descripción completa

Detalles Bibliográficos
Autores principales: Stücker, Sabrina, Kresin, Nico, Carrier, Lucie, Friedrich, Felix W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Physiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539082/
https://www.ncbi.nlm.nih.gov/pubmed/28824454
http://dx.doi.org/10.3389/fphys.2017.00558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539082/
https://www.ncbi.nlm.nih.gov/pubmed/28824454
http://dx.doi.org/10.3389/fphys.2017.00558

Ejemplares similares